CHEST Physician
-
Top reads from the CHEST journal portfolio – December 2025
Read new research from the journal portfolio about IL-5-targeted biologic therapies, correct nasogastric tube placement, and the association of hypoxic burden with cardiovascular events.
-
Third trial supports sotatercept to treat PAH
Guidelines expert James R. Klinger, MD, FCCP, said that while the evidence of efficacy is clear, more research is needed to address questions regarding the optimal duration of therapy and the potential for disease progression if therapy is stopped.
-
Study demonstrates strong patient compliance with oral device for OSA
Evidence suggests that an oral device may be an effective alternative for patients who can’t access or tolerate CPAP therapy.
-
The climate cost of inhalers: What prescribers should know
Experts said clinicians must ensure patients have the therapies they need at affordable prices that, ideally, impose minimal amounts of environmental harm.
-
Update from the 2025 Council of Networks
Deborah Jo Levine, MD, MS, FCCP, Chair of Council of Networks, shares the highlights that made CHEST 2025 such a huge success for the community on the membership level.
-
Phase 3 IMPALA-2 clinical trial shows inhaled molgramostim promising for autoimmune pulmonary alveolar proteinosis
An ongoing 96-week, open-label period of the trial is designed to shed light on the drug’s long-term safety and efficacy.
-
Oseltamivir found to lower risk of flu-linked neuropsychiatric events in children
This study is the largest and most comprehensive US investigation of the drug and severe neuropsychiatric events, said author James Antoon, MD, PhD, MPH.
-
Data suggest pneumococcal vaccination is underused
Respiratory medicine expert Christina Thornton, MD, PhD, said recent real-world data demonstrate high rates of community-acquired pneumonia driven by serotypes targeted by vaccines.
-
Early data suggest air pollution may initiate lung cancer
Researcher Peiyao Wang said early results show that fine particulate matter is causing permanent DNA damage, which could have implications for lung cancer screening.
-
Making it stick: Rapid pleurodesis for MPE offers faster freedom from IPCs
Rapid pleurodesis combines prompt symptom control with the potential for pleural symphysis in a shorter time frame, allowing for potential lifestyle benefits while minimizing the risk of IPC-related complications.
